It is exciting thinking of what has been going on behind the scenes that shareholders as yet have not been made aware.

BP certainly haven't been quietly sitting on their collective asses waiting for a deal before doing deep, deep investigating into what will be needed to bring the IBD and possibly even further Brilacidin indications closer to commerciality.

Those that keep their focus on the rear view mirror really don't belong in biotech IMO. Biotech is for those with forward vision only.

I would dearly love to get a state of the company newsletter from Leo soon after the EMA meeting.